Launching novel oncology therapies in Asia: Identifying and communicating value
Novel cancer therapies are offering patients new treatments and better outcomes worldwide. Recent changes in healthcare policies across APAC have reignited interest in the region as a strong market for oncology, such as China's fast tracking approval of therapies for severe and rare diseases and Vietnam's plan to cover health insurance for 80% of the population. Unfortunately, the often eye-watering costs of these new therapies means that, currently, for the many patients who still have to pay for treatment out of pocket, novel therapies are beyong reach. Pharma brands need to demonstate clear value if they want to achieve success.
Market access in Brazil: All eyes on Spinraza
Director Rachel Howard asks, “What does Brazil’s unprecedented risk-sharing agreement in Spinal Muscular Atrophy (SMA) mean for the future of market access in Brazil?
In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde (SUS). This is the first agreement in Brazil to include a risk-sharing model, in which the government only pays for the drug if there is improvement in the patient's health. In a country where it typically takes years for innovative pharmaceutical products to be reimbursed in the public sector, manufacturers wishing to obtain market access for their products in Brazil will be watching this example closely to see how it plays out.
Research Partnership continues to expand in the US
We are pleased to announce a number of appointments across our US offices.
Mariana Servin has joined the company’s New York office as Quantitative Director. Mariana has over 18 years’ experience in market research and consulting for pharmaceutical, biotech, medical device and life science clients. She has worked in senior roles for a variety of research and advisory organisations including Quintiles Consulting, Decisions Resources Group and Ipsos Healthcare. Mariana has a wealth of experience in both qualitative and quantitative research, including global work covering Europe, Asia-Pacific and Latin American markets. She joins Research Partnership with a remit for supporting the quantitative side of the business, especially in advanced analytics.
Therapy Watch appoints new Associate Director
Research Partnership is delighted to welcome Mark Hollis who has joined the Therapy Watch team in London.
Mark has 8 years’ experience in syndicated healthcare, and previously worked in the Market Prognosis team at IQVIA (IMS Health), where he led field work, analytics, forecasting and report writing for the Middle East and North Africa region.
Sabera Hyderally appointed Head of MedTech North America
Research Partnership is delighted to welcome Sabera Hyderally who has joined the company’s US headquarters in Philadelphia.
Sabera has over 20 years’ experience in market research, specifically on the agency side. Most recently she was at Lieberman where for the last 7 years she held the position of Executive Vice President of Health.